Showing results (121-130 of 151) with videos related to

Sort By:
Pageof 16
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2023
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN TrialKevin Kalinsky, Melissa K Accordino, Codruta Chiuzan, et al.
JAMA Oncology|April 12, 2019
Current Landscape of Immunotherapy in Breast Cancer: A ReviewSylvia Adams, Margaret E Gatti-Mays, Kevin Kalinsky, et al.
Future Oncology (London, England)|June 30, 2023
TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancerAditya Bardia, Komal Jhaveri, Kevin Kalinsky, et al.
Clinical Breast Cancer|December 18, 2021
Diagnosis of Leptomeningeal Metastasis in Women With Breast Cancer Through Identification of Tumor Cells in Cerebrospinal Fluid Using the CNSide™ AssayMargaux Wooster, Julia E McGuinness, Kathleen M Fenn, et al.
Scientific Reports|February 28, 2025
Gene expression associated with endocrine therapy resistance in estrogen receptor-positive breast cancerVeronica Jones, Hongwei Holly Yin, Yate-Ching Yuan, et al.
NPJ Breast Cancer|July 20, 2017
Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trialKerin Adelson, Bhuvaneswari Ramaswamy, Joseph A Sparano, et al.
JAMA Oncology|December 11, 2025
Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical TrialIrene M Kang, Jamie K Forschmiedt, Michelle M Loch, et al.
NPJ Breast Cancer|October 12, 2019
Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancerDavid B Page, Harry Bear, Sangeetha Prabhakaran, et al.
Clinical Breast Cancer|May 8, 2025
Expert Perspectives on Controversies and Critical Knowledge Gaps in Breast Cancer Management: Proceedings of the First Bridging the Gaps in Breast Cancer SymposiumKomal Jhaveri, Carey K Anders, Aditya Bardia, et al.
Nature Cancer|December 30, 2022
Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancerTizita Z Zeleke, Qingfei Pan, Codruta Chiuzan, et al.
Pageof 16